Rilotumumab
- Generic Name
- Rilotumumab
- Drug Type
- Biotech
- CAS Number
- 872514-65-3
- Unique Ingredient Identifier
- 51WEW898IJ
- Background
Rilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.
A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer
Phase 3
Terminated
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2014-05-13
- Last Posted Date
- 2016-04-04
- Lead Sponsor
- Amgen
- Target Recruit Count
- 34
- Registration Number
- NCT02137343
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ
Phase 1
Completed
- Conditions
- Part 1- Advanced Solid TumorsPart 2- Advanced or Metastatic Gastric CancerPart 2- Advanced or Metastatic GEJ
- Interventions
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2016-02-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 21
- Registration Number
- NCT01791374
- Locations
- 🇯🇵
Research Site, Suntou-gun, Shizuoka, Japan
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 3
Terminated
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 609
- Registration Number
- NCT01697072
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma
Phase 2
Completed
- Conditions
- Malignant Neoplasm of EsophagusMalignant Neoplasm of Stomach
- Interventions
- First Posted Date
- 2011-09-29
- Last Posted Date
- 2020-11-17
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 162
- Registration Number
- NCT01443065
- Locations
- 🇫🇷
Institut Gustave Roussy, Villejuif, France
AMG 102 and Avastin for Recurrent Malignant Glioma
- First Posted Date
- 2010-04-29
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Katy Peters
- Target Recruit Count
- 36
- Registration Number
- NCT01113398
- Locations
- 🇺🇸
The Preston Robert Tisch Brain Tumor Center, Durham, North Carolina, United States
QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer
Phase 1
Terminated
- Conditions
- Extensive-stage Small Cell Lung CancerLung CancerSolid TumorsSmall Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- NantCell, Inc.
- Target Recruit Count
- 213
- Registration Number
- NCT00791154
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
Phase 1
Completed
- Conditions
- Colorectal CancerMetastatic Colorectal CancerRectal CancerGastrointestinal CancerColon Cancer
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- NantBioScience, Inc.
- Target Recruit Count
- 177
- Registration Number
- NCT00788957
AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer
Phase 1
Completed
- Conditions
- CancerCastrate-Resistant Prostate CancerMestastatic Prostate CancerProstate Cancer
- Interventions
- First Posted Date
- 2008-10-10
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 162
- Registration Number
- NCT00770848
AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer
Phase 1
Completed
- Conditions
- Gastric CancerEsophageal CancerEsophagogastric Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2013-12-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 130
- Registration Number
- NCT00719550
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath